Sports Medicine
No difference in function between stem cells and control during microfracture
Regen Ther. 2019;(11):106-113. doi: 10.1016/j.reth.2019.06.002The authors randomized 14 patients who were undergoing microfracture to two groups: one group received bone marrow-derived mesenchymal stem cells (BMSCs), and the other group were controls. Outcomes included the Knee Injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC), T2 time on magnetic resonance imaging, and the Magnetic Resonance Observation Cartilage Repair Tissue (MOCART) scoring system. Scores were collected at 6, 12, 24 and 48 weeks after surgery. There was no significant difference on most functional outcome scores or T2 values between the two groups. The intervention group did have significantly higher (better) MOCART scores at 24 and 48 weeks post-operative.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
